Seniors Had High Burden of RSV-Positive Respiratory Infection Before COVID-19
Following sharp decline during COVID-19, RSV-positive acute respiratory infection reemerged during summer 2021, and is linked to lower QOL
Following sharp decline during COVID-19, RSV-positive acute respiratory infection reemerged during summer 2021, and is linked to lower QOL
Pfizer-BioNTech bivalent vaccine under investigation; Trial evaluating HIV prevention vaccine discontinued; Early detection sepsis test cleared; Trial results for RSV-associated disease vaccine; Combo Tx for HCC recurrence shows promise.
Results showed vaccine efficacy of 83.7% against RSV-LRTD, defined by 2 or more symptoms.
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
Nirsevimab is a long-acting anti-RSV for nirsevimab for the prevention of RSV lower.
Decision comes as the nation suffers from an unusually early and hard flu season, with about 9,300 deaths so far
Medication limits are meant to ‘ensure equitable access,’ according to a CVS statement
Every household in the country is eligible to receive four free COVID-19 nasal swab testing kits
The BLA is supported by data from the phase 3 RENOIR trial which included approximately 37,000 adults 60 years of age and older.
Vaccination will be key to keeping patients healthy through the winter holidays